# Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

> **NCT00481871** · PHASE1,PHASE2 · COMPLETED · sponsor: **Acrotech Biopharma Inc.** · enrollment: 119 (actual)

## Conditions studied

- Relapsed or Refractory Lymphoproliferative Malignancies
- Hodgkin's Lymphoma
- Peripheral T-cell Lymphoma
- B-cell Lymphoma
- Waldenstrom's Macroglobulinemia

## Interventions

- **DRUG:** Pralatrexate Injection
- **DRUG:** Gemcitabine Hydrochloride
- **DIETARY_SUPPLEMENT:** Vitamin B12
- **DIETARY_SUPPLEMENT:** Folic Acid

## Key facts

- **NCT ID:** NCT00481871
- **Lead sponsor:** Acrotech Biopharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2011-05
- **Final completion:** 2011-08
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2020-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00481871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00481871, "Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00481871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*